Skip to main content

Drug Interactions between bifidobacterium infantis and loracarbef

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

loracarbef bifidobacterium infantis

Applies to: loracarbef and bifidobacterium infantis

ADJUST DOSING INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.

MANAGEMENT: Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.

References (3)
  1. Clarion Brands, Inc. (2020) Florajen Probiotics. https://www.florajen.com/products/florajen-women
  2. Xiao JZ, Takahashi S, Odamaki T, Yaeshima T, iwatsuki k (2010) "Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market." Biosci Biotechnol Biochem, 74, p. 336-42
  3. dwyer a (2024) Taking probiotics with antibiotics https://www.optibacprobiotics.com/learning-lab/in-depth/general-health/probiotics-with-antibiotics

Drug and food interactions

Moderate

loracarbef food

Applies to: loracarbef

ADJUST DOSING INTERVAL: Loracarbef may exhibit reduced gastrointestinal absorption in the presence of food. When loracarbef capsules were administered with food, the peak plasma concentrations were 50% to 60% of concentrations after administration in a fasting state and were reached 30 to 60 minutes later. Area under the concentration-time curve (AUC) was not affected. The therapeutic effect of the antimicrobial may be reduced.

MANAGEMENT: Loracarbef should be administered at least one hour before or two hours after eating.

References (1)
  1. (2002) "Product Information. Lorabid (loracarbef)." Lilly, Eli and Company

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer